SANUWAVE HEALTH, INC. (OTCMKTS:SNWV) Files An 8-K Results of Operations and Financial Condition
Item 2.02
Results of Operations and Financial Condition.
On March 29, 2019, SANUWAVE Health, Inc., a Nevada Corporation (the “Company”), announced its financial results for the year ended December 31, 2018 and provided a business update via conference call. A copy of the related press release is furnished as Exhibit 99.1 to this Form 8-K. A copy of the transcript of such call is furnished as Exhibit 99.2 to this Form 8-K.
The information in this Item 2.02 of this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1
Press release, dated March 29, 2019, issued by SANUWAVE Health, Inc., titled “SANUWAVE Health reports record 2018 financial results; Full year revenue increased over 150%.”
99.2
Transcript of the March 29, 2019, SANUWAVE Health, Inc. conference call to discuss 2018 financial results and provide a business update.
SANUWAVE Health, Inc. Exhibit
EX-99.1 2 snwv_ex991.htm PRESS RELEASE Blueprint Exhibit 99.1 FOR IMMEDIATE RELEASE SANUWAVE HEALTH REPORTS RECORD 2018 FINANCIAL RESULTS FULL YEAR REVENUE INCREASED OVER 150% SUWANEE,…
To view the full exhibit click here
About SANUWAVE HEALTH, INC. (OTCMKTS:SNWV)
SANUWAVE Health, Inc. is an acoustic pressure shock wave technology company using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The Company is focused on regenerative medicine utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, enabling to restore the body’s normal healing processes and regeneration. It is focused on developing its Pulsed Acoustic Cellular Expression (PACE) technology to activate healing in wound conditions.
